43
Corporate Presentation 上海君实生物医药科技股份有限公司 Shanghai Junshi Biosciences Co., Ltd.*
Corporate Presentation上海君实生物医药科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
2
Disclaimer
The information, statements and opinions contained in this Presentation and subsequent discussion (if any) do not constitute an offer to sell or solicitation of any offer to subscribe for or purchase any securities or other financial instruments or any advice or recommendation in respect of such securities or other financial instruments in any jurisdiction. In particular, this Presentation is not an offer of securities for sale nor a solicitation of an offer to buy securities.
Potential investors and shareholders of the Company (the “Potential Investors and Shareholders”) are reminded that information contained in this Presentation and subsequent discussion (if any) comprises extracts of operational data and financial information of the Group for the nine months ended 30 September 2020. The information included in this Presentation and subsequent discussion (if any), which does not purport to be comprehensive nor render any form of financial or other advice, has been provided by the Group for general information purposes only and certain information has not been independently verified. It may not contain all of the information that you may consider material. No representations or warranties, expressed or implied, are made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, statements or opinions presented or contained in this Presentation and any subsequent discussions or any data which such information generates. Potential Investors and Shareholders should refer to The Third Quarterly Report for 2020 for the unaudited results of the Group which are published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
The performance data, the results of operations and the clinical development of the drug candidates of the Group contained in this Presentation and subsequent discussion (if any) are historical in nature, and past performance is no guarantee of the future results of the Group. Any forward-looking statements and opinions contained in this Presentation and subsequent discussion (if any) are based on current plans, beliefs, expectations, estimates and projections at the date the statements are made, and therefore involve risks and uncertainties. The words “aim”, “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, going forward”, “intend”, “may”, “plan”, “predict”, “project”, “potential”, “seek”, “will”, “would”, the negative of these terms and similar expressions, as they relate to us, are intended to identify forward-looking statements. There can be no assurance that any of the matters set out in such forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. Actual results may differ materially and/or adversely from those stated, implied and/or reflected in such forward-looking statements and opinions. The Group, affiliates, the Directors, officers, employees, agents, representatives and advisers of the Group assume (a) no obligation to correct, update or supplement the forward-looking statements or opinions contained in this Presentation and subsequent discussion (if any), whether as a result of new information, future events or otherwise; and (b) no liability in the event that any of the forward-looking statements or opinions do not materialise or turn out to be incorrect
This Presentation may also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this Presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk
Potential Investors and Shareholders should exercise caution when investing in or dealing in the securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional adviser(s)
01
Company Overview
4
Introduction
Founded in
December 2012
International Strategic
Operations
Stand on the Frontline
against COVID-1929 Drug Candidates
in Pipeline
At the forefront of R&D for large molecule drugs
An EUA request has been filed by our partner LLY for JS016, the NAb to combat COVID-19
Covering therapeutic areas including cancer, autoimmune, metabolic, neurological and
infectious diseasesR&D centers and manufacturing facilities
1st
PRC company to commercialized anti-PD-1 mAb
PRC company to receive IND approval for anti-PCSK9 mAb
Globally First-in-Human anti-BTLA antibody IND approved by US FDA
First-in-Human Clinical Trials with SARS-CoV-2 NAb approved by NMPA
Commercialized(NRDL)
NDA Accepted in
November 2019
EUA filed in November
2020
Preclinical
1
1
1
17
2 Phase II
ShanghaiSuzhou
Maryland
San Francisco
Phase I5
Guangzhou
Beijing
2 Phase III
1st neutralizing human monoclonal antibody against SARS-CoV-2 in China, pre-clinical research completed in 4 months
Combination with LY-CoV555 reduced viral load, symptoms, and COVID-related hospitalizations and ER visits
5
Seasoned Executive Management Team
Mr. Ma Jun
Deputy General Manager
◼ Over 20 years of experience in the engineering
design and construction (EDC) industry
Dr. Patricia Keegan
CMO
◼ 30 years of experience at the FDA
Dr. Yao Sheng
Executive Director & Deputy General Manager
◼ Inventor of six registered patents or patents in application
◼ Rich experience in the area of pharmaceutical R&D and clinical
research
Dr. Wang Gang
CQO & Deputy General Manager
◼ Lead inspector at the FDA
◼ Chief scientist at CDE
◼ Extensive experience in the area of quality management
Mr. Duan Xin
CCO & Deputy General Manager
◼ Over 20 years of experience
in multiple MNCs
Mr. Xie Wan
Deputy General Manager
◼ Over 20 years of experience in the
pharmaceutical industry
Mr. Yin Kan
Deputy General Manager
◼ Over 20 years of experience in the
pharmaceutical industry
Mr. Xiong Jun
Chairman & Executive Director
◼ Over 20 years of experience in both of financial and healthcare industry
◼ Served senior management roles at various pharmaceutical companies since 2013
◼ Inventor of six registered patents or patents in application
◼ Rich experience in the area of pharmaceutical R&D and clinical
research
Dr. Li Ning
Executive Director, CEO & General Manager
◼ 13 years of experience at the FDA
◼ Mainly responsible for formulating business strategies and
managing operations of our Group
Dr. Feng Hui
Executive Director & COO
◼ Over 10 years of industry experience in
biotechnology and drug discovery
Mr. Zhang Zhuobing
Executive Director & Deputy General Manager
◼ Over 20 years of experience in the
pharmaceutical industry
Dr. Yao Sheng
Executive Director & Deputy General Manager
◼ Extensive experience in the area of pharmaceutical R&D
and clinical research
◼ Inventor of six registered patents or patents in application
Dr. Wu Hai
Non-executive Director
◼ Over 10 years of experience in the pharmaceutical industry
◼ Published about 20 articles in academic journals such as
Nature, Science and EMBO
6
Robust Pipeline: Core Product – JS001: Toripalimab, PD-1
Therapeutic
AreasCandidates Targets Indications Pre clinical Phase I Phase II Phase III NDA Area Note
JS001
ToripalimabPD-1
2L Melanoma (Ph II Pivotal Trial) China NDA approved
3L NPC (Ph II Pivotal Trial) China Received Priority Review
3L NPC (Ph II Pivotal Trial) US FDA BTD and ODD
2L UC (Ph II Pivotal Trial) China Received Priority Review
1L NPC Global Met primary endpoint (interim)
1L NSCLC (SCC + non-SCC) China Met primary endpoint (interim)
1L Esophageal squamous cell cancer China 2021 NDA
EGFR+ NSCLC China 2021 NDA
1L Melanoma China 2022 NDA
1L HCC (+ Bevacizumab) China 2022 NDA
TNBC China 2022 NDA
1L SCLC China 2022 NDA
NSCLC Neoadjuvant China 2022 NDA
3L GC
(Phase II Registration Trial)China Expect to file the NDA after 2023
1L RCC China Expect to file the NDA after 2023
1L HCC (+Lenvatinib) Global Global multicenter study
Mucosal melanoma US FDA orphan drug designation
Sarcoma US FDA orphan drug designation
HCC Adjuvant China Expect to file the NDA after 2023
1L UC PD-L1+ Global
Oncology
7
Robust Pipeline: Other Clinical Stage Programs
Therapeutic
AreasCandidates Targets Indications Pre clinical Phase I Phase II Phase III NDA Area Note
JS003 PD-L1 Solid tumors China
JS004 BTLA
Melanoma, lung cancer, lymphoma, etc. US Dose-Escalation completed in US
Melanoma, lung cancer, lymphoma, etc. China
JS101 Pan-CDK Breast cancer, etc. China
JS501 VEGF NSCLC, colorectal cancer, etc. China
JS108 TROP2 Triple negative breast carcinoma, small
cell lung cancer, pancreatic cancerChina
JS109 PARP1L Ovarian Cancer Maintenance
TreatmentChina
JS109 PARP 3L BRCA-mutated ovarian cancer China
Ongericimab
JS002 PCSK9 Hyperlipidemia China
JS005 IL17A Psoriatic, ankylosing spondylitis China
UBP1211 TNF-αRheumatoid arthritis, ankylosing
spondylitis, psoriasisChina
UBP1213 BLyS Systemic lupus erythematosus ChinaExpected to change the dosage form
and apply for IND in 2021
JS016Etesevimab
S-protein COVID-19
USCombination therapy met
endpoints in a Phase II Trial
China
Oncology
Infectious
disease
Metabolic
Auto-
immunity
8
Robust Pipeline: Preclinical Stage Programs
Therapeutic
AreasCandidates Targets Indications Origins
Commercial
RightsNote
JS006 TIGIT Solid tumors In-house Global 2020 IND
JS007 CTLA-4 Lung cancer, melanoma In-house Global
JS009 CD112R/PVRIG Solid tumors In-house Global 2021 IND
JS011 (Undisclosed) (Undisclosed) In-house Global
JS012 (Undisclosed) (Undisclosed) In-house Global 2021 IND
JS104 CDK Breast cancer, etc. 50% Rights in-licensing Global 2021-2022 IND
JS105 PI3K-α Breast cancer, kidney cancer, etc. 50% Rights in-licensing Global 2021 IND
JS014 IL-21 Solid tumors 100% Rights in-licensing China 2021 IND
JS018 IL-2 Solid tumors 100% Rights in-licensing Global
JS019 CD39 Solid tumors 50% Rights, Joint Venture China 2021 IND
JS201 PD-1/TGF-β Solid tumors In-house Global 2021 IND
JS110 XPO1 Multiple myeloma, etc. 50% Rights in-licensing Global2021 IND
JS111 EGFR E20 ins NSCLC 50% Rights in-licensing Global 2021 IND
JS112 Aurora A SCLC, etc. 50% Rights in-licensing Global 2021 IND
JS113 EGFR 4th Gen NSCLC 50% Rights in-licensing Global 2021 IND
Metabolic JS008 (Undisclosed) (Undisclosed) In-house Global
Neurologic JS010 CGRP Migraine In-house Global 2022 IND
Oncology
9
Recent Business Progress
Robust and Comprehensive Pipelines
Toripalimab: First and Most Wide-ranging in China
Toripalimab: Internationally Competitive and Globally Strategic
COVID-19 NAb
Active BD
• 29 drugs candidates
• 1 approved and now expanding indications, 1 submitted NDA, 1 submitted EUA
and is in phase 3 studies, another 2 are in phase 3 studies
• Including monoclonal antibodies, BsAbs, ADCs and small molecule drugs
• Encompassing 5 major therapeutic areas
• Became the 1st PRC company to commercialize PD-1 on Dec 17, 2018
• Toripalimab was added to the NRDL
• Covers the widest range of indications
• NDA for NPC and UC are in the process of priority review. NDA for 1L NSCLC
and 1L NPC are prepared for submission
• The first patient was dosed with JS001 in the Phase 3 Clinical Trial for 1L HCC
and 1L RCC
• Closest to commercialized Chinese PD-1 in the US, and strategic planning on a
Global Platform
• Toripalimab for treatment of NPC received the BTD. This is the first anti-PD-1
antibody from China to receive the BTD
• Toripalimab for the treatment of patients with mucosal melanoma, NPC and
Sarcoma received the ODD• More indications planned for launch in the US market
• In June 2020, JS016 jointly developed with IMCAS was approved
for an international multi-center clinical trial
• In mid-November, an EUA request was submitted to the FDA by
our partner Lilly for combination therapy with LY-CoV555 and
JS016
• The BLA for combination therapy is expected to be submitted as
early as Q2 2021
• Entered Phase 2/3 clinical trials in early December
• More than 10 partners
• Collaborated with Revitope in the R&D of next-generation T-cell
engaging cancer immunotherapies
• In-licensed a CD39 drug in Greater China through joint venture
• Co-developed the clinical trial and commercialization of PARP
inhibitor through joint venture with IMPACT
• In-licensed 4 drug candidates（XPO1/AuroraA/ EGFR-exom20/
EGFR 4th Gen）from Wigen Biomedicine
• Obtained a worldwide license for the IL-2 drug from Leto
Laboratories
• In-licensed anti-HSA-IL-2Nα series products in Greater China
02
Core Commercialized
Product
11
Our Core Product —— JS001 (Toripalimab, anti-PD-1 mAb)
High affinity
Strong internalization induction
The binding affinity of JS001 for PD-1 is about 0.3 nm as measured
by Biacore T200
The results show high binding affinity of JS001, which enables it to
bind more firmly to the PD-1 receptors on T-cells and better prevent
the binding between PD-1 and PD-L1/PD-L2 on tumor cells.
Upon binding with the PD-1 receptor, JS001 blocks the interaction of PD-1 with PD-L1 and
PD-L2 and simultaneously induces the internalization of the PD-1 receptor, thereby
decreasing the expression of PD-1 on the surface of the cell membrane
The bottom-right graphs show a decrease in PD-1 expression on the cell surface during
internalization of JS001 by simultaneously staining the JS001 non-competitive anti-PD-1
monoclonal antibody (clone MIH4). A decrease in PD-1 expression can improve the reactivity
of T-cells to the antigen. This mechanism does not rely on PD-1 ligand (PD-L1) expression
Immunofluorescence assay
resultsFlow cytometry results
Unique CDR sequences and binding
domains: PD-1 FG loop
IP: IgG4/Kappa (CN104250302B）
（PCT WO2014/206107A1）
C’D loop
N terminal loop
PD-1FG loop
Distinct binding characteristics
“ Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.”Liu H. et al. mAbs 11(4):681-690. doi: 10.1080/19420862.2019.1596513. Epub 2019 Apr 19.
12
The Latest Clinical Data of Toripalimab (JS001)
Melanoma
Esophageal Squamous Cell CarcinomaNasopharyngeal Carcinoma
Lung cancer
Urothelial Cancer
≥2L，Mono，N=128：ORR: 17.3%，DCR: 57.5%，mPFS: 3.6 mo，mOS: 22.2 mo
1L，Mucosal Melanoma，+Axitinib，N=33：ORR: 48.5%，DCR: 86.2%，mPFS: 7.5 mo，mOS: 20.7 mo
≥2L，Mono, N=190：ORR: 20.5%，DCR: 41.6%，mPFS: 1.9 mo，mOS: 18.6 mo
1L， +SC, N=12：ORR: 75%，DCR: 83.3%
≥2L，Mono，N=151：ORR: 25.8%，DCR: 45.0%，mPFS: 2.3 mo，mOS: 14.4 mo
EGFR + NSCLC，+PEM/CARBO，N=40：ORR: 50%，DCR: 87.5%，mPFS: 7 mo
≥2L NSCLC，Mono，N=41：ORR: 7.1%，DCR: 39.3%，mPFS: 2.8 mo，mOS: 13.8 mo
≥2L，Mono，N=59：ORR：18.6%，DCR: 47.5%
1L，+SC，N=12：ORR：66.7%，DCR: 91.7%
1L，+NabP/S-1 Neoadjuvant Therapy，N=24：ORR: 79.2%，DCR: 100%
Biliary Tract Tumors1L，+GS, N=39：ORR: 20.6%，DCR: 85.3%，mPFS: 6.7 mo
Intrahepatic Cholangiocarcinoma1L，+GEMOX/Lenvatinib, N=30：ORR: 80%，DCR: 93.3%
Colorectal Cancer≥3L， +Regorafenib, N=12：ORR=15.2%, DCR: 36.4%，mPFS: 2.6 mo，mOS: 15.5 mo
Pancreatic Adenocarcinoma1L，+AG, N=11：ORR: 27.3%，DCR: 81.8%，mPFS: 7 mo
Renal Cell Carcinoma
≥2L，+Axitinib，N=32：ORR: 25%，DCR: 84%，mPFS: 14.8 mo
Neuroendocrine Neoplasms≥2L，Mono，N=40：ORR: 20%, DCR: 35%, mPFS: 2.5 mo, mOS: 7.8 mo
Solid Tumors≥2L，Mono，N=36：ORR: 22.2%, DCR: 50%, mPFS: 2.8 mo, mOS: 12.2 mo
≥2L，+Sulfatinib，N=29：ORR: 34.5%, DCR: 79.3%
Lymphoma≥2L，Mono，N=11：ORR: 90.9%, DCR: 90.9%, mPFS: 8.3 mo
• Sources：ASCO 2019/2020, AACR 2020, CSCO 2020. ESCO 2020, ESMO 2020
Pivotal Trial
NDA
Submitted
Pivotal Trial
NDA
Submitted
Pivotal Trial
Approved
13
Toripalimab Pivotal Trials Layout and Strategy
Toripalimab Clinical Development Strategy
Adjuvant/Neoadjuvant ≥ 2nd LineFirst Line
China U.S. & EU
Major Indication
• NSCLC (EGFR WT and Mut)
• Esophageal cancer (EC)
• Hepatocellular carcinoma(HCC)
• Gastric cancer (GC)
• NSCLC
• Hepatocellular carcinoma
Niche Indication
• Melanoma
• Nasopharyngeal carcinoma (NPC)
• Urothelial carcinoma (UC)
• Triple-negative breast cancer (TNBC)
• Renal cell carcinoma (RCC)
• Small Cell Lung Cancer (SCLC)
• Soft tissue sarcoma
• Nasopharyngeal carcinomaODD&BTD
• Mucosal melanomaODD
• Soft tissue sarcomaODD
ODD: FDA Orphan Drug Designation
BTD: FDA Breakthrough Therapy Designation
UC
Mono single arm
Melanoma
Mono single arm
NPC
Mono single arm
GC
Mono single arm
HCC Adjuvant
Mono vs Placebo
NPC
Combo vs chemo
Melanoma
Mono vs Dacarbazine
NSCLC EGFR(-)
Combo vs Chemo
NSCLC EGFR(+)
Combo vs chemo
TNBC
Combo vs albumin-bound paclitaxel
EC
Combo vs chemo
SCLC
Combo vs Chemo
NSCLC Neoadjuvant
Combo vs Chemo
HCC
Combo with Avastin vs Sorafenib
RCC
Combo with Axitinib vs Sunitinib
Approved
HCC
Combo with Lenvatinib vs Lenvatinib
NDA
Submitted
UC PD-L1(+)
Combo vs Chemo
Reach pre-specified
primary endpoint
NDA
SubmittedReach pre-specified
primary endpoint
14
Toripalimab in NPC
Source: 2020 ASCO Poster
In April 2020, the NDA for Toripalimab as a treatment for patients with recurrent/metastatic nasopharyngeal carcinoma who failed at least two lines of systemic therapy was accepted by NMPA. This is the world’s first NDA of anti-PD-1 monoclonal antibody for the treatment of recurrent/ metastatic nasopharyngeal carcinoma.
In September 2020, this therapy received the FDA's Breakthrough Therapy Designation.
Currently, the results from the interim analysis for first-line treatment has shown that the primary endpoint was achieved.
As of Feb 19, 2020, among all 190 patients assessed by an
Independent Review Committee, 5 complete responses, 34 partial
responses and 40 stable diseases were observed, for an objective
response rate of 20.5%, and disease control rate of 40.0%. For 92
2L+ patients, the objective response rate was 23.9%.
The response was durable as the median DOR was 14.9 months.
The median PFS was 1.9 months and the median OS was 17.4
months.
15
Toripalimab in Lung Cancer
Note: NP/TP/GP/DP/AP: cisplatin or carboplatin (P) plus gemcitabine (G), docetaxel (D), paclitaxel (T), vinorelbine (N) or pemetrexed (A)Source: CSCO (Chinese Society of Clinical Oncology), Goldman Sachs Global Investment Research, Internal Estimation
Targeted therapy/chemo
1st-line (1L)
Gefitinib, erlotinib, afatinib,
icotinib
2nd-line (2L)
-Local/slow progression:
continue original TKI
-Rapid progression:
T790M+: osimertinib or 2-drug
regimen(NP/TP/GP/DP/AP)
T790M-: 2-drug
regimen(NP/TP/GP/DP/AP)
3rd-line (3L)
Targeted therapy/chemo
1st-line (1L)
Crizotinib or 2-drug
regimen(NP/TP/GP/DP/AP)
2nd-line (2L)
Locally and slowly progression
-continue original TKI
Rapid progression-2-drug
regimen(NP/TP/GP/DP/AP)
Chemo+RT
cisplatin+
etoposide/
taxanes/
pemetrexed
Chemo only
Chemo
Cisplatin+
paclitaxel/
vinorelbine
Chemo or CRT
Chemo
2-drug regimen
(NP/TP/GP/DP/AP)
Neoadjuvant
Best practise
remains under discussion
Non-squamous cell
1st-line (1L)2-drug regimen(NP/TP/GP/DP/AP) or w/o platins2nd-line (2L)Mono: docetaxel, pemetrexed
Squamous cell
1st-line（1L）2-drug regimen
(NP/TP/GP/DP)or w/o platins
2nd-line (2L)
Mono: docetaxel
Surgery
Resectable Unresectable EGFR+ ~48% ALK+ ~6% w/o driver oncogenes ~41%
I-III ~40% IV ~60%
SCLC ~10%
NSCLC ~90%
Lung cancer 733k
SCLC
combo vs chemo
NSCLC EGFR(-)
combo Vs chemo
NSCLC EGFR(+)
combo vs chemo
NSCLC Neoadjuvant
Toripalimab vs Placebo
16
EGFR+ Advanced NSCLC Patients Who Failed Prior EGFR TKI Therapies
Patients with TP53 co-mutation responded significantly better in ORR than TP53
wild type patients (62% vs 14%) .
➢ 90% (36/40) patients had target lesion decreased from baseline
➢ 60% (24/40) patients had target lesion reduced more than 30%A Phase II, multicenter, open-label, single-arm study for patients with EGFR
activating mutations who have failed prior EGFR-TKI therapies without T790M
mutation or failed Osimertinib treatment.
As of Jan 2, 2020, among all 40 patients, 20 confirmed partial responses and 15
stable disease were observed for a 50.0% ORR (95% CI, 33.8% to 66.2%) and an
87.5% DCR (95% CI, 73.2% to 95.8%).
Median PFS was 7.0 months, while median DOR was 7.0 months.
PD-L1+ patients ORR 60.0%, mPFS 8.3 months versus PD-L1- patients ORR 39%,
mPFS 5.7 months
17
Timeline of Pivotal Clinical Trials
sNDAFPI
Primary
Readout 17
Timeline of Pivotal Clinical Trials
Jan/18 Jul/18 Jan/19 Jul/19 Jan/20 Jul/20 Jan/21 Jul/21 Jan/22 Jul/22 Jan/23 Jul/23 Jan/24 Jul/24 Jan/25
NPC 1L
NSCLC 1L
ESCC 1L
NSCLC EGFR+ TKI failed
Melanoma 1L
HCC combo Avastin
TNBC 1L
SCLC 1L
NSCLC Neoadjuvant
GC 3L(P2)
RCC 1L
HCC Adjuvant
HCC combo Lenvatinib
03
Covid-19 NAb
Update
19
Process Development and Production
Using a platform manufacturing process to
shorten development time for monoclonal
antibodies
➢ Transient transfection：Platform-based small-scale
production process. In the process of production
scale-up and simultaneously scaling up research
➢ Stable transfection：A platform-based 2000L scale
stable transfection technology
Flexible use of transient and stable transfection
processes to meet the requirements for phased
samples
➢ 5L, 25L, 200L fast transient transfection production of
hundreds of grams samples for product quality,
efficacy and toxicology research
➢ 2000L GMP stable transfection production of tens of
thousands of grams samples for clinical research
➢ The adoption of single-use technology to reduce
production time
Pre-clinical research completed in 4 months, fast entry into clinical trials
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
2020 2021
Vectors Pool screen MCB testing
Pooled material
Tox material
Transient material
Process, formulation,
analytical dev
Vectors Pool screen Stable pool testing
Pre-Tox, pharmacology, PK, GLP Tox studies
DPGMP DS DP stability
Tox, release, stability, UPB, VC
final reports prior to dosing
SubcloneMCB/WCB
banking
UPB/VC
IND
Accelerated
Clone screen Cell line stability
Process, formulation, analytical dev
Pharmacology, PK, GLP Tox studies
GMP DS/testing DP/testing Stability
UPB/VC
IND
Traditional
High quality, high expression, high purity and high
yield
➢ High-density cell culture: Yields >7 g/L
➢ Product purity: >99%
➢ High product yield: >70%
20
License-Out COVID-19 Neutralizing Antibody to Lilly
• In May 2020, we entered into a Research Collaboration and License Agreement with Lilly. Pursuant to the Agreement, the parties would collaborate in the research, development and commercialization of products relating to SARS-CoV-2 neutralizing antibodies (JS016), and Lilly was granted an exclusive license to conduct research and development activities, make and sell Junshi SARS-CoV-2 Antibodies outside of Greater China
Our company granted an exclusive license to, among others,
conduct R&D activities, make and sell of JS016 outside of Greater
China
Double-digit royalties on the net sales of the product
Lilly paid to our company an upfront fee of US$10 million
Milestone payments of up to US$245 mn for each SARS-CoV-2
antibody (two antibody candidates in JS016)
Licensed Terms
Both parties established a Joint Steering
Committee to oversee and coordinate the R&D
of Junshi SARS-CoV-2 Antibodies
We will, in collaboration with Lilly, continue to
press forward with an IND application for
antibodiesR&D Cooperation
21
Clinical
A randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy
and safety of LY-CoV555 and LY-CoV016 in participants with mild to moderate COVID-
19 illness
Interim Results
New data show that combination treatment with LY-CoV555 and LY-CoV016 reduced
viral load, symptoms, and COVID-related hospitalizations and ER visits
Exploratory Analysis
Exploratory analysis shows that combination therapy is better at avoiding the putative
resistance variants
Regulatory
Submitted an EUA request for combination therapy in mid-November
Combination Therapy Clinical Trial
22
Combination Therapy Clinical Trial
VIRAL LOAD CHANGE FROM BASELINE
PRE-SPECIFIED ANALYSIS
PRE-SPECIFIED ANALYSIS
PROPORTION OF PATIENTS WITH PHVL ( LOG (VIRAL LOAD) ≥ 5.27 ), DAY 7
1PHVL (Persistently High Viral Load) is defined as Log(viral load) ≥ 5.27. This cut-point was determined based on pooled hospitalization and viral load data from the LY-CoV555 monotherapy cohort, prior to receipt of combination data. Ongoing cohorts incorporate this measure as a pre-specified endpoint.
23
HOSPITALIZATION AND ER VISITS ( WITHIN 28 DAYS AFTER
TREATMENT )HOSPITALIZATION AND ER VISITS IN HIGHER-RISK PTS
Combination Therapy Clinical Trial
04
Pipeline Expansion
25
TAB004 /JS004 First in Human Anti-BTLA Antibody for Solid Tumors
BTLA is a parallel checkpoint with PD-1 to regulate lymphocyte activation.
PD-1-like molecule expressed on activated T- and B-cells
In animal models of autoimmunity and inflammation (RA, SLE, EAE and
Asthma), BTLA-deficient mice show enhanced T-cell activation and have
exacerbated disease
HVEM overexpressed in tumors and suppressed T-cell function through BTLA
BTLA co-expresses with PD-1 on tumor specific T-cells from human melanoma
and non-small cell lung cancer patients
BTLA blockade promotes antigen-specific T-cell response and works
synergistically with toripalimab (anti-PD-1)
The IND application was approved by the FDA and the NMPA in April
2019 and January 2020, respectively; no competitor in clinical stage
BTLA
IgV
HVEM BTLA
Activated T-cells, B-cells
Macrophage, DC, B-cells, T-cells,
Epithelial and Endothelial cells,
Neuronal cells
Overexpressed on tumors
Inhibitory signal
26
TAB004 /JS004 First-in-Human Anti-BTLA Antibody for Solid Tumors
NCT04278859 / CTR20200202 NCT No. NCT04137900
Interventional (Clinical Trial) Study Type Interventional (Clinical Trial)
200Estimated
Enrollment 144
Non-Randomized Allocation Non-Randomized
None (Open Label) Masking None (Open Label)
A Phase I Clinical Study of JS004, a Recombinant Humanized
mAb Specific to B-and T-Lymphocyte Attenuator (BTLA), in
Subjects With Advanced Solid Malignancies in China
Official Title
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-
Escalation and Cohort Expansion Study to Evaluate the Safety,
Tolerability, and Pharmacokinetics of TAB004 in Subjects With Advanced
Solid Malignancies Including Lymphoma
March 31, 2020Actual Study Start
Date October 30, 2019
July, 2022Estimated
Completion Date January, 2023
In April 2019, TAB004/ JS004 was approved by the U.S. FDA for clinical trials and is the world’s first anti-BTLA monoclonal antibody for injection approved for clinical trials
In January 2020, the IND application for TAB004/JS004 was approved by the NMPA
In October 2019, the first patient was dosed in the U.S and in April 2020, the first patient was dosed in China
27
Other Core Products In Development——Metabolic & Auto-immune
JS002
JS002 is a recombinant humanized anti-PCSK9
monoclonal antibody for injection independently
developed by the Company for the treatment of
cardiovascular diseases.
The Company is the first PRC company to
obtain clinical trial approval for the target drug.
We have completed the Phase I clinical trial with
the clinical trial center Fuwai Hospital to test the
safety and tolerability of JS002 on voluntary
subjects. At present, the Phase II clinical trial
has been completed.
Currently, the initiation of Phase III clinical
studies with a larger patient population is
underway.
JS005
JS005 is a recombinant humanized anti-IL-
17A monoclonal antibody injection that
targets autoimmune diseases including
psoriasis.
In preclinical studies, JS005 has shown
efficacy and safety comparable to those of
marketed anti-IL-17 monoclonal antibodies.
In May 2020, the first subject was dosed in
a Phase I clinical study of JS005 (a
recombinant humanized anti-IL-17A
monoclonal antibody for injection) in China.
At present, the Phase I clinical study has
completed random enrollment.
a recombinant humanized anti-TNF-α-monoclonal
antibody injection, which targets autoimmune
diseases such as rheumatoid arthritis and is a
biosimilar of Humira
(Adalimumab)
UBP1211
The Company has submitted an NDA
application for UBP1211 to NMPA and it
was accepted in November 2019
28
JS009: Anti-CD112R Monoclonal Antibody
◼ CD112R(PVRIG), a inhibitory
immune checkpoint.
◼ Treatment of T cells with anti-
CD112R in combination with PD-1
or TIGIT inhibitors further increased
T cell activation, improved the
effect of clinical treatment
◼ JS009 shows much more potent than COM701 in enhancing T
cell activation and exhibits a significant synergistic effect when
combined with JS006 and JS001.
Our Goal: Best in Class
-1 0 1 2 3 450000
100000
150000
JS009
COM701
EC50
JS009
18.02
COM701
74.72
Log( mAbs concen(ng/mL))
RL
U
JS009 Mono reporter Assay
JS009 combination with 0.3μg/mL of JS006
-1 0 1 2 3 450000
100000
150000
200000
250000
COM701 +0.3μg/mL JS006
JS009
JS009 +0.3μg/mL JS006
Log(JS009 concen(ng/mL))
RL
U
EC50
JS009
11.95
JS009 +0.3μg/mL JS006
19.09
COM701 +0.3μg/mL JS006
163.7
0 2 4 60
600000
1200000
JS001 combination with JS006 and JS009
log(JS001 concen(ng/mL))
RL
U
JS006+JS009+JS001 dose
JS006+COM701+JS001 dose
JS001 dose
0.3ug/ml JS006+JS001 dose
Mono Reporter Assay
Dual-luciferase Reporter Assay Triple-Luciferase Reporter Assay
◼ JS009 has the potential to be the highest titer
monoclonal antibody drug in house
Titer of JS009K52 140SC64
6 8 9 10 12 14
0
1
2
3
4
5
6
7
8
9
10
Time (day)
Tit
er
(g/L
)
Cell line development-Fedbatch
9.7g/L
12.9 g/L
Cell culture development-5L Bioreactor
Rationale
29
JS014: Engineered IL-21 with Half-life Extender
Significantly improved PK profile
2 4 4 8 7 2 9 6 1 2 0
0 . 1
1
1 0
1 0 0
1 0 0 0
T i m e ( h )
ng
/m
L
r h I L 2 1 , 0 . 1 5 m g / k g
J S 0 1 4 , 0 . 1 5 m g / k g
Balb/c mice, IP injection, Single dose
C57BL/6 mice, IP injection, BIWx3W
0 10 20 30
0
1000
2000
3000
MC38 WT Tumor
Days after the start of tumor inoculation
Tu
mo
r vo
lum
e (
mm
3)
Saline
JS014 0.42mg/kg
JS014 1.25mg/kg
JS014 3.75mg/kg
rhIL21 0.625mg/kg
Improved anti-tumor efficacy and in synergy with JS001
PD-1 KI C57BL/6 mice, IP injection, BIWx3W
Anti-HSA
NanobodyIL-21
Half-life Extender
IL-21-hαHSA (No linker)
JS014 Molecule Structure
◼ Formulation and Delivery system: solution
injection, IV
◼ Storage and shelf life: 2~8℃, no less than 2 years
◼ Purity: monomer≥95%, aggregate ≤5%
Improved stability and developability
0 2 4 4 8 7 2
1
1 0
1 0 0
1 0 0 0
1 0 0 0 0
T i m e ( h )
0 . 1 m g / k g
0 . 5 m g / k g
ng
/m
l
Cyno monkey, IV injection, Single dose
30
JS019: Anti-CD39 Monoclonal Antibody
Completed stable cell line development, DS process and
formulation development, two lots of non-GMP production
at 200L scale for preclinical studies
Completed pre-Tox study, JS019 shows good tolerance up
to 200 mg/kg
◼ JS019 and Gemcitabine combo shows tumor growth inhibition effect.
◼ Good tolerance up to 200 mg/kg in the preliminary toxicity evaluation.
Group Dosage (mg/kg) Animals (F/M)
1 20 1/1
2 200 1/1
Single dose, 28-day observation
Results: No toxicity was observed for both groups
CD39 is an ectonucleotidase on the ATP-Adenosine
pathway, the inhibition of CD39 not only prevents the
accumulation of immunosuppressive adenosine, but also
stabilizes the pro-inflammatory extracellular ATP to restore
antitumor immunity.
Mechanism of Action
Current Status
Results
31
JS201: Bifunctional Fusion Protein Simultaneously Targeting PD-1 and TGF-β
Anti-PD-1 mAb (Toripalimab)
TGF-βRII ECD
◼ Dual blockade of PD-1 and TGF-β signaling promote superior T cell activation than monotherapy in
MLR assay
◼ In vivo efficacy and PK/PD profile in Cyno with NOAEL of 100mg/kg indicate promising better efficacy
than monotherapy, and tolerate safety
0 1 0 2 0 3 0 4 0 5 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
D a y s p o s t t u m o r i n o c u l a t i o n
Tu
mo
r
vo
lu
me
(
mm
3
)
T G F β T r a p C o n t r o l , 1 0 m g / k g
T o r i p a l i m a b ( P D - 1 m A b ) , 1 0 m g / k g
J S 2 0 1 , 1 0 m g / k g
MiXeno model- NCG /Melanoma (A375)
◼ Improved stability and developability
➢ Storage at 2~8℃, no less than 2 years
➢ Purity: monomer≥95%, aggregate ≤5%
05
Future Milestones
33
Prospective Achievements in 2021
NDA Approvals NDA/BLA Submissions
Preclinical Candidates
Data Readouts
⚫ Humira biosimilar
⚫ Toripalimab for NPC
⚫ Toripalimab for UC
⚫ About 15 candidates to file IND or Pre-IND meeting
⚫ Toripalimab for 1L ESCC
⚫ Toripalimab for EGFR+ NSCLC
⚫ BTLA Phase I
⚫ Senaparib interim
⚫ Toripalimab for NPC BLA [US]
⚫ Toripalimab for 1L NPC NDA [China]
⚫ Toripalimab for 1L NSCLC BLA/NDA [China & US]
⚫ Toripalimab for 1L ESCC NDA [China]
⚫ Toripalimab for NSCLC EGFR+ TKI failed NDA [China]
⚫ Etsevimab (combo with Bamlanivimab) for Covid-19[US]
06
Appendix
35
Our History and Achieved Milestones
• Established
as a limited
liability
company in
the PRC
• Listed on NEEQ • Completed the merger
by absorption of
Shanghai Union
Biopharm (previously
listed on the NEEQ,
stock code:
430598.NEEQ)
• Wujiang GMP facility
completed construction
• Initiated construction
of Lingang GMP
manufacturing facility
• Toripalimab IND
approval from the
NMPA, the first
anti-PD-1
monoclonal
antibody
developed by a
PRC company to
receive IND
approval in Dec
2015.
• UBP1211(Humira
Biosimilar) IND
approved by the
NMPA
• Toripalimab began
its first clinical trial
• JS002 received IND
approval, the first
anti-pcsk9
monoclonal
antibody developed
by a PRC company
to obtain IND
approval from the
NMPA
• Clinical trials began in
the United States for
Toripalimab
• JS003(PD-L1)
obtained IND approval
from the NMPA.
• Anti-BTLA (First-in-
Human Globally)
IND was approved
by FDA
• IL-17A IND was
approved by the
NMPA
• Toripalimab approved
for 2nd line treatment
of metastatic
melanoma on
12/17/2018 by the
NMPA
• Listed on main board
of HKEX (stock
code:1877.HK) on
12/24/2018
• Revenue reached
RMB774M ($110M
USD) from 2/26/2019
to 12/31/2019
• Obtained the drug
production license for
Lingang GMP
manufacturing facility
• BLA was submitted for
Humira Biosimilar
• Initiated
construction of
Wujiang GMP
manufacturing
facility
~20 FTEs
2012 2018 201920162015
• Toripalimab IND
filed to NMPA
2014
~50 FTEs ~100 FTEs ~200 FTEs ~300 FTEs ~700 FTEs ~1300 FTEs
• Anti-BTLA IND was approved by the NMPA in January
• Collaborated with the IMCAS to develop COVID-19
neutralizing antibody (JS016)
• The NMPA and the FDA approved JS016 as an IND in
June 2020, the R&D and commercialization rights of
JS016 outside Greater China was out-licensed to LLY.
• In July 2020, NDA filings of Toripalimab for NPC and
UC received priority review status
• Listed on the SSE STAR Market on July 15, 2020,
stock code: 688180
2020
~2000 FTEs
2017
• Toripalimab for treatment of NPC, soft tissue
sarcoma, melanoma (+Axitinib) were granted
orphan-drug designations by the FDA, and its
treatment of NPC received the BTD granted by the
FDA
• Submitted EUA request to the FDA for combination
therapy with LY-CoV555 and JS016 in mid-
November
• In November, the first patient was dosed in the Phase
1 clinical trial of JS108
• Anti-TIGIT monoclonal antibody (JS006) IND
application was accepted by the NMPA
• Toripalimab was added to the NRDL
36
Competitive Positioning Backed by Fully Integrated R&D Platform
Human Transmembrane Receptor Protein Array
and High-throughput Screening Platform
◼ Encompasses close to 5,000 human cell membrane
proteins
◼ Increased avidity and a highly sensitive detection
system
◼ Continuously expands the monoclonal antibody
product line for cell surface receptors and soluble
proteins
Automated High-efficiency Screening Platform for
Antibody Selection and Functional Assays
◼ Greatly broadens the initial range of clinical drug
candidate screening
◼ Helps to find optimal candidates
◼ Provides us with a basis for our R&D of innovative
monoclonal antibodies and functional screening in vitro
and in vivo
High-yield Stable Expression Cell Lines Screening and
Establishment Platform
◼ Based on the internationally leading GS expression system
(LONZA)
◼ To complete the establishment of high expression cell lines with
significantly faster speed and higher titers than the traditional
DHFR technology
Antibody Quality Research, Control
and Assurance Platform
◼ Covering the quality assurance
regarding suppliers, inputs, process,
outputs and customers
◼ Ensuring our compliance with GMP
standards
CHO Cell Fermentation
Process Development
Platform
Antibody Humanization and
Construction Platform
Antibody Purification Process
Development and Formulation
Optimization Platform
37
Enhance Pipeline Through Business Development
Co-development for an Avastin biosimilar
with Huaota Biosciences
◼ HOT-1010/JS501 is a recombinant humanized anti-
VEGF monoclonal antibody injection that has received
clinical trial approval from the NMPA and is in Phase I
clinical trial.
◼ Selectively binds to human VEGF and blocks its
biological activity, mainly used for the treatment of
metastatic CRC and advanced, metastatic or recurrent
NSCLC.
Co-development for an anti-Trop2
monoclonal antibody – Tub196 conjugate
with DAC Biotech
◼ DAC-002/JS108 is an anti-Trop2 monoclonal antibody conjugated
with an ant-itubulin Tubulysin B analog through a smart linker.
◼ Mainly used to treat solid tumors such as Trop2-positive TNBC,
SCLC and PC. Currently, an application for clinical trials has been
submitted to and has been accepted by NMPA.
◼ The Company currently holds approximately 4.28% in the shares of
DAC Biotech.
Co-development for a novel IL-21 fusion protein with
Anwita
◼ IL-21 is an active cytokine that stimulates the activation of innate and adaptive
immune cells, such as natural killer (NK) cells and cytotoxic T-cells.
◼ AWT008 is Anwita’s proprietary IL-21 fusion protein with a prolonged half-life
and improved in vivo antitumor activities in animal models. It is intended for
development as single agent or in combination with other therapeutic agents.
◼ Subscribed for 20% of Anwita’s outstanding shares.
Co-development for the next-generation of T-cell
engaging cancer immunotherapies with Revitope
◼ The parties will collaborate in the research and development of the next-
generation of T-cell engaging cancer immunotherapies that utilize Revitope’s
proprietary dual-antigen targeting technology platform together with the
Company’s antibody technology platform
◼ Revitope's unique approach is based on a pair of tumor-targeted antibodies
with a shared T-cell engaging domain which act as inactive pro-drugs unless
they encounter cancer cells co-expressing both antigens.
◼ Revitope will be responsible for designing up to 5 unique T-cell
immunotherapeutic drugs against targets selected by the Company.
Co-development for a small-molecule
PARP inhibitor with IMPACT
◼ IMP4297 (Senaparib), a novel agent targeting PARP
(poly-ADP ribose polymerase), has completed two
Phase I studies in China and Australia
◼ Preliminary data indicates that Senaparib has the
potential to be the best-in-class PARP inhibitor with a
better safety profile and a wider therapeutic window
Beijing
Co-development for an IL-2 drug with Leto
Laboratories
◼ Interleukin 2 (IL-2) is a globular glycoprotein that plays
an important role in maintaining the normal functions of
T-lymphocyte and NK cell
◼ LTC002 has adopted a unique and innovative way to
eliminate the interaction with α receptor subunits.
Therefore, it may be beneficial to increase the
effectiveness of treatment and reduce its side effects
Suzhou
Co-development for two drug candidates
with Risen pharma
◼ A pan-CDK inhibitor that can effectively inhibit the
activity of a number of cyclin-dependent kinases,
including CDK-1, CDK-2, CDK-4, CDK-6 and CDK-9.
◼ An oral ɑ-specific PI3K inhibitor.
Nanjing Shanghai Hangzhou
San Francisco Cambridge
Co-development for a CD39 drug with
Beijing Eirene
◼ CD39 is the enzyme responsible for the initial steps in
the conversion of immune stimulatory extracellular ATP
to immunosuppressive adenosine in the tumor
microenvironment
◼ JS019 can achieve high efficacy and reduce potential
systemic side effects by selectively targeting the
immunosuppressive cells with high CD39 expression in
the tumor microenvironment.
Co-development for four drug candidates with
Wigen Biomedicine
◼ JS110 is an oral broad-spectrum antitumor small molecule
drug
◼ JS111 is a targeted small molecule inhibitor that effectively
inhibits EGFR exon20 insertion mutants.
◼ JS112 is an oral small molecule Aurora A inhibitor.
◼ JS113 is an effective fourth-generation EGFR inhibitor.
38
No-binding co-
development
CM082(VEGF),
Sulfatinib(VEGF),
APG1387(IAP),
ATG-008(mTOR),
Donafenib(Multi-target),
Lucitanib(Multi-target),
Simmitecan(Topo1),
JAB-3068(SHP2)
TAB008(VEGF)
TJ-D5(CD73)
YH001(CTLA-4)
HBM4003(CTLA-4)
GFH018(TGF-βR1)
AL8326(Multi-target）Mavorixafor(CXCR4）
…
In-House
JS004(BTLA),
JS005(CTLA-4),
JS006(TIGIT)…
In-licensed
JS104(CDK),
JS105(PI3k),
JS501(Avastin Biosimilar),
JS014(IL-21),
JS108(TROP2 ADC)
JS109(PARP)
JS018(IL-2)
JS019(CD39)
01 02 03
Well-Structured PD-1 Combo Solution
39
Antibody-drug Conjugates (ADCs) : Biological Missiles
Unit：Thousand
◼ In December 2019, the Company gained the exclusive
license for DAC-002 (JS108) from DAC Biotech
◼ JS108 comprises Trop2 monoclonal antibody and analogue
of Tubulysin B covalently conjugated through smart linker
◼ In July 2020, JS108 received IND approval from the NMPA
About JS108
Anti-
Trop2
mAb
Smart
linker
Antitubulin
tubulysin B
analog
◼ Trop2 is a transmembrane glycoprotein encoded by the Tacstd2 gene. Trop2 is expressed in
many cancers and the overexpression of Trop2 is of prognostic significance.
◼ According to Frost & Sullivan, lung cancer is the most common type of cancer in China with
895,300 new cases in 2019, while breast cancer is the most common type of cancer in women
with 326,200 new cases in 2019.
TNBC SCLC Pancreatic
cancer
Structure of JS108
Potential Market
Indications
0 200 400 600 800 1000
INCIDENCE OF CANCERS WITH TROP2 OVEREXPRESSION IN 2019
lung cancer
gastric cancer
colorectal cancer
thyroid carcinoma
breast cancer
esophageal cancer
head and neck carcinoma
cervix uteri cancer
pancreatic cancer
non-hodgkin's lymphoma
cholangio-carcinoma
urinary bladder carcinoma
gallbladder
glioma
40
TEAC Tumor-specific Immunotherapies
Dual-targeting
two-component TEAC
Conventional
BsAb
Metastases
Immune
activation
Tumor
Background
Tumors typically do not express cell surface proteins unique to tumors,
therefore, conventional bispecific antibody therapeutics can generate
unwanted and substantial “on-target, off-tumor” toxicity. Revitope’s
two-component T-cell engaging antibodies are designed to reduce
systemic toxicity by specifically enhancing the recruitment and activation
of T-cells at tumor sites.
Though developed with traditional tumor targeting domains, TEAC therapies uniquely split the CD3
paratope (the T-cell recognition domain) into two molecules. This allows for dual-antigen targeting to a
unique tumor-specific sites – two inputs coming together to enable one precise targeted output. Only
when the two molecules come together through binding to their different tumor targets on the same
tumor cell can the two halves of the CD3 binding domain recombine and create a fully functional anti-
CD3 domain (a TEAC).
Mechanism of
Action
Junshi and Revitope will collaborate in the research and development of the next-generation of T-cell engaging cancer immunotherapies
Revitope will be responsible for designing up to 5 unique T-cell immunotherapeutic drugs against targets selected by the Company
41
IL-2 Drug with Intramolecular Disulfide Bonds
IL-2的双重药理作用限制了其临床应用
◼ IL-2 has adopted a unique and innovative way to prevent binding to IL2Rα by
introducing additional disulfide into IL-2
◼ The additional disulfide can keep IL-2 more structurally stable and forms a
barrier that allows the IL-2 molecule to destroy the conjunct plane within the α
receptor with minimal changes.
◼ The new designed mutants cannot bind to the endogenous α receptors in the
body, but can bind to β and γ receptor subunits. Therefore, it inhibits the
stimulatory effects of IL-2 on Tregs, while maintaining the stimulatory effects on
effector T-cells, NK cells and other immune cells – effectively maximizing the
anti-tumor activity of the IL-2 drug
IL-2 binds to two different receptor forms:
IL-2 signaling is initiated when IL-2 binds to either the IL-2R αβγ complex or the
IL-2Rβγ complex; however, the two binding affinities are different
◼ At high affinity, it engages the IL-2R αβγ complex expressed on CD4+
immunosuppressive regulatory T-cells
◼ The IL-2R αβγ complex is also expressed on type-2 innate lymphoid cells
and eosinophils. These cells mediate vascular leak syndrome (VLS),
hypotension, pulmonary edema, and liver and kidney shock
◼ At lower affinity, IL-2 engages the IL-2Rβγ complex expressed on CD8+ T
and NK cells. These cells are critical for anti-tumor responses
Background
About LTC002
42
Financial Highlights
Dual Listing
Assets and Cash
Expenses
Q1-Q3 2020 revenue of RMB
1.0 billion
+92% yoy, including RMB
724 million Toripalimab sales
and RMB 276 million milestone
payments
Q1-Q3 2020 total assets of RMB 8.1
billion (+84%,yoy), net assets
attributable to owners of the company
of RMB 6.4 billion (+113%,yoy), cash
and cash equivalents of RMB 4.1
billion (+146%,yoy)
Q1-Q3 2020 R&D expense of RMB 1.2
billion (+97%,yoy)supports a robust pipeline
of 28 drug candidates, 12 of which have
entered clinical trials, and 16 ongoing
clinical trials of Toripalimab (PD-1)
Q1-Q3 2020 total expense of RMB 1.9
billion R&D expense is the biggest expense
item and accounts for 63% of total expense
Q1-Q3 2020 net loss of RMB 1.1 billion due
to continuous R&D commitment
Listed on SSE STAR market
(stock code:688180) on July
15, 2020.The total amount
raised is RMB 4.836
billion
Listed on main board of HKEX
(stock code:1877.HK) on Dec.
24, 2018. The net amount
raised is HKD 3.413
billion
The 1st“H+A share” biotech
company under Chapter 18A
of HKEX and the 5th set of
listing standards of STAR
market
Total Revenue
The financial data is from 2020 unaudited third quarterly report which is prepared in accordance with the accounting principles of the PRC.
Thank You！
